These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 35877035)

  • 21. The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions.
    Lehoux D; Kallend D; Wijngaard PLJ; Brown AP; Zerler B
    Pharmacol Res Perspect; 2023 Apr; 11(2):e01080. PubMed ID: 37021909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
    Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
    N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials.
    Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D
    S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease.
    Nishikido T
    Cardiovasc Diabetol; 2023 Jan; 22(1):20. PubMed ID: 36717882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inclisiran and cardiovascular events: a comprehensive review of efficacy, safety, and future perspectives.
    Mohamed AA; Ray KK
    Curr Opin Cardiol; 2023 Nov; 38(6):527-532. PubMed ID: 37522763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inclisiran, the billion-dollar drug, to lower LDL cholesterol - is it worth it?
    Doggrell SA
    Expert Opin Pharmacother; 2020 Nov; 21(16):1971-1974. PubMed ID: 32749892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.
    Dutta S; Shah R; Singhal S; Singh S; Piparva K; Katoch CDS
    Expert Opin Drug Saf; 2024 Feb; 23(2):187-198. PubMed ID: 38063346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on inclisiran for the treatment of elevated LDL cholesterol.
    Barkas F; Ray K
    Expert Opin Pharmacother; 2024 Mar; 25(4):349-358. PubMed ID: 38549399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia.
    Ebenezer O; Comoglio P; Wong GK; Tuszynski JA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies.
    Chan DC; Watts GF
    Clin Ther; 2023 Nov; 45(11):1034-1046. PubMed ID: 37524569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review.
    Merćep I; Friščić N; Strikić D; Reiner Ž
    Cardiovasc Ther; 2022; 2022():8129513. PubMed ID: 35237348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
    Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A
    Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
    Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translational Population-Pharmacodynamic Modeling of a Novel Long-Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia.
    Gosselin NH; Schuck VJA; Barriere O; Kulmatycki K; Margolskee A; Smith P; He Y
    Clin Pharmacol Ther; 2023 Feb; 113(2):328-338. PubMed ID: 36281788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inclisiran-New hope in the management of lipid disorders?
    Dyrbuś K; Gąsior M; Penson P; Ray KK; Banach M
    J Clin Lipidol; 2020; 14(1):16-27. PubMed ID: 31879073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.
    Brandts J; Ray KK
    Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany.
    Makhmudova U; Schatz U; Perakakis N; Kassner U; Schumann F; Axthelm C; Stürzebecher P; Sinning DL; Doevelaar A; Rohn B; Westhoff T; Vogt A; Scholl M; Kästner U; Geiling JA; Stach K; Mensch J; Lorenz E; Paitazoglou C; Eitel I; Baessler A; Steinhagen-Thiessen E; Koenig W; Schulze PC; Landmesser U; Laufs U; Weingärtner O;
    Clin Res Cardiol; 2023 Nov; 112(11):1639-1649. PubMed ID: 37422840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
    Fitzgerald K; White S; Borodovsky A; Bettencourt BR; Strahs A; Clausen V; Wijngaard P; Horton JD; Taubel J; Brooks A; Fernando C; Kauffman RS; Kallend D; Vaishnaw A; Simon A
    N Engl J Med; 2017 Jan; 376(1):41-51. PubMed ID: 27959715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
    Mahmood T; Shapiro MD
    Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.